Other Notices

Omega Announces Delisting from Nasdaq

March 20, 2025

Omega Therapeutics, Inc. (the “Company”) announced today that it will file a Form 25 to withdraw its common stock from listing and registration on the Nasdaq Global Select Market.  The Company expects that the delisting will occur ten days after the filing of the Form 25, on or around March 31, 2025.  As previously disclosed, on February 18, 2025, Company received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq had determined to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”). Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company’s commencement of the Chapter 11 Case on February 10, 2025. The Notice also indicated that concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, including Listing Rule 5450(a)(1), served as an additional and separate basis for the delisting decision. Trading of the Common Stock was suspended at the opening of business on February 25, 2025.  Following the delisting of the Company’s Common Stock from Nasdaq, the Company intends to file a Form 15 with the Securities and Exchange Commission on or about March 31, 2025 to suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the filing of the Form 25 and the Form 15. The timing of events could differ materially from those anticipated in such forward-looking statements as a result of important risks and uncertainties, including without limitation risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-lookin